Biofrontera Inc. Contracts & Agreements
70 Contracts & Agreements
- Business Finance (34 contracts)
- Business Operations (10)
- Human Resources (14)
- Intellectual Property (6)
- Uncategorized (6)
- Description of Securities (Filed With SEC on March 15, 2024)
- Amended and Restated Business Loan and Security Agreement between Biofrontera Inc. and Agile Capital Funding, LLC and Agile Lending, LLC, dated as of December 21, 2023 (Filed With SEC on March 15, 2024)
- Business Loan and Security Agreement between Biofrontera Inc. and Cedar Advance, LLC, dated as of December 21, 2023 (Filed With SEC on March 15, 2024)
- Form of Series B-3 Convertible Preferred Stock Warrant (Filed With SEC on February 23, 2024)
- Form of Securities Purchase Agreement, dated February 19, 2024, by and amount Biofrontera Inc. and the purchasers named therein (Filed With SEC on February 23, 2024)
- Placement Agency Agreement, dated February 19, 2024, by and between Biofrontera Inc. and Roth Capital Partners, LLC (Filed With SEC on February 23, 2024)
- Second Amended and Restated License and Supply Agreement, dated February 19, 2024, between the Company, Pharma and Bioscience (Filed With SEC on February 20, 2024)
- Release of Claims, dated February 13, 2024, between the Company, Pharma and Bioscience (Filed With SEC on February 20, 2024)
- Amended and Restated Addendum to Amended and Restated License and Supply Agreement, dated January 29, 2024 (Filed With SEC on February 2, 2024)
- Form of Placement Agent Agreement (Filed With SEC on January 29, 2024)
- Form of Warrant (Filed With SEC on January 29, 2024)
- Form of Pre-Funded Warrant (Filed With SEC on January 29, 2024)
- Form of Securities Purchase Agreement (Filed With SEC on January 29, 2024)
- Confidential Settlement Agreement and Mutual Release, dated as of December 27, 2023 and effective as of December 22, 2023, by and between the Company and Maruho (Filed With SEC on January 3, 2024)
- Addendum to Amended and Restated License and Supply Agreement, dated as of December 12, 2023 (Filed With SEC on December 15, 2023)
- Form of Common Warrant (Filed With SEC on November 2, 2023)
- Form of Pre-Funded Warrant (Filed With SEC on November 2, 2023)
- Securities Purchase Agreement, dated October 30, 2023, by and between Biofrontera Inc. and an institutional investor (Filed With SEC on November 2, 2023)
- Placement Agency Agreement, dated October 30, 2023, by and between Biofrontera Inc. and Roth Capital Partners, LLC (Filed With SEC on November 2, 2023)
- Amendment to Common Stock Purchase Warrants, dated October 30, 2023, by and between Biofrontera Inc. and institutional investor (Filed With SEC on November 2, 2023)
- Amendment No. 1 to Settlement Agreement dated as of October 12, 2023, between Biofrontera Inc., Hermann Luebbert, John J. Borer, Loretta M. Wedge, Beth J. Hoffman, Kevin D. Weber... (Filed With SEC on October 13, 2023)
- Confidential Settlement and General Release Agreement, dated as of May 25, 2023, between the Company and Erica Monaco (Filed With SEC on August 11, 2023)
- Settlement Agreement dated April 11, 2023 between Biofrontera Inc., Hermann Luebbert, John J. Borer, Loretta M. Wedge, Beth J. Hoffman, Kevin D. Weber and Biofrontera AG (Filed With SEC on May 12, 2023)
- Commitment Letter dated as of March 9, 2023 between the Company and MidCap Business Credit LLC (Filed With SEC on May 12, 2023)
- Loan and Security Agreement, dated as of May 8, 2023, between the Company, as Borrower, and MidCap Business Credit LLC, as Lender (Filed With SEC on May 12, 2023)
- Amendment No. 1 to the Stockholder Rights Agreement, dated as of April 26, 2023, between Biofrontera Inc. and Computershare Trust Company, N.A., as Rights Agent (Filed With SEC on April 28, 2023)
- Description of Securities (Filed With SEC on March 13, 2023)
- Biofrontera Inc. 2021 Omnibus Incentive Plan (as amended and restated on December 12, 2022) (Filed With SEC on December 16, 2022)
- Form of Exchange Agreement (Filed With SEC on October 31, 2022)
- Employment Agreement dated October 3, 2022 (Filed With SEC on October 24, 2022)
- Form of Inducement Letter (Filed With SEC on July 28, 2022)
- Form of Inducement Warrant (Filed With SEC on July 28, 2022)
- Summary of Director Compensation (Filed With SEC on May 24, 2022)
- Form of Purchaser Warrant (Filed With SEC on May 20, 2022)
- Form of Pre-funded Warrant (Filed With SEC on May 20, 2022)
- Form of Securities Purchase Agreement (Filed With SEC on May 20, 2022)
- Form of Registration Rights Agreement (Filed With SEC on May 20, 2022)
- Description of Securities (Filed With SEC on April 11, 2022)
- Amended Settlement Allocation Agreement dated as of March 31, 2022 between the Company and Biofrontera AG (Filed With SEC on April 5, 2022)
- Amendment to Employment Agreement effective as of April 1, 2022 Erica Monaco (Filed With SEC on April 5, 2022)
- Amendment to Amended Employment Agreement effective as December 15, 2021 and dated March 2, 2022 Herman Lbbert (Filed With SEC on March 8, 2022)
- Form of Purchaser Warrant (Filed With SEC on December 3, 2021)
- Form of Pre-Funded Warrant (Filed With SEC on December 3, 2021)
- Form of Unit Purchase Option (Filed With SEC on December 3, 2021)
- Form of Securities Purchase Agreement (Filed With SEC on December 3, 2021)
- Form of Registration Rights Agreement (Filed With SEC on December 3, 2021)
- Underwriting Agreement dated October 28, 2021 among the Company and the Representatives (Filed With SEC on November 3, 2021)
- Warrant Agent Agreement dated November 2, 2021 among the Company, the Trust Company and Computershare (Filed With SEC on November 3, 2021)
- Form of Underwriting Agreement (Filed With SEC on October 26, 2021)
- Form of Warrant Agent Agreement (Filed With SEC on October 26, 2021)
- Corrected Amendment to Amended and Restated License and Supply Agreement dated October 8, 2021 by and among Biofrontera Pharma GmbH, Biofrontera Bioscience GmbH and Biofrontera Inc (Filed With SEC on October 13, 2021)
- Form of Underwriting Agreement (Filed With SEC on October 12, 2021)
- Specimen Stock Certificate evidencing the shares of common stock (Filed With SEC on October 12, 2021)
- 2021 Omnibus Incentive Plan (Filed With SEC on October 12, 2021)
- Form of Restricted Stock Unit Executive Award Agreement under 2021 Omnibus Incentive Plan (Filed With SEC on October 12, 2021)
- Form of Nonqualified Stock Option Executive Award Agreement under 2021 Omnibus Incentive Plan (Filed With SEC on October 12, 2021)
- Form of Nonqualified Stock Option Award Agreement under 2021 Omnibus Incentive Plan (Filed With SEC on October 12, 2021)
- Employee Stock Purchase Plan (Filed With SEC on October 12, 2021)
- Amendment to Amended and Restated License and Supply Agreement dated October 8, 2021 by and among Biofrontera Pharma GmbH, Biofrontera Bioscience GmbH and Biofrontera Inc (Filed With SEC on October 12, 2021)
- Amended Employment Agreement dated October 1, 2021 Hermann Lbbert (Filed With SEC on October 1, 2021)
- Amended and Restated Master Contract Services Agreement dated September [__] 2021, by and among the Company, Biofrontera AG, Biofrontera Pharma GmbH and Biofrontera Bioscience GmbH (Filed With SEC on September 16, 2021)
- Intercompany Services Agreement dated January 1, 2016, between the Company, Biofrontera AG, Biofrontera Pharma GmbH and Biofrontera Bioscience GmbH (Filed With SEC on September 16, 2021)
- Amended Employment Agreement Hermann Lbbert (Filed With SEC on September 16, 2021)
- Employment Agreement Erica Monaco (Filed With SEC on August 12, 2021)
- Employment Agreement Hermann Lbbert (Filed With SEC on August 12, 2021)
- Quality Agreement dated November 1, 2016, between the Company and Biofrontera Pharma GmbH (Filed With SEC on July 26, 2021)
- Amended and Restated License and Supply Agreement dated June 16, 2021 by and among Biofrontera Pharma GmbH, Biofrontera Bioscience GmbH and Biofrontera Inc (Filed With SEC on July 6, 2021)
- Employment Agreement Erica Monaco (Filed With SEC on July 6, 2021)
- Second Intercompany Revolving Loan Agreement dated March 31, 2021 by and between the Company and Biofrontera AG (Filed With SEC on July 6, 2021)
- Master Contract Services Agreement dated July 2, 2021, by and among the Company, Biofrontera AG, Biofrontera Pharma GmbH and Biofrontera Bioscience GmbH (Filed With SEC on July 6, 2021)